Plant viruses as nanoparticle-based vaccines and adjuvants

Vaccines

Volumn 3, Issue 3, 2015, Pages 620-637

  Lebel, Marie ève ^a   Chartrand, Karine ^a   Leclerc, Denis ^b   Lamarre, Alain ^a  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Adjuvant; Immune response; Production methods; Recombinant plant virus; Vaccine

Indexed keywords

B LYMPHOCYTE RECEPTOR; COAT PROTEIN; NANOPARTICLE; PATTERN RECOGNITION RECEPTOR; UNCLASSIFIED DRUG; VIRUS LIKE NANOPARTICLE; VIRUS VACCINE;

ALFALFA MOSAIC VIRUS; ANTIGEN EXPRESSION; CELLULAR IMMUNITY; COWPEA MOSAIC VIRUS; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; GENE EXPRESSION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; NONHUMAN; PAPAYA MOSAIC VIRUS; PLANT VIRUS; POTATO VIRUS X; REVIEW; TOBACCO MOSAIC VIRUS; VACCINATION; VIRUS REPLICATION;

EID: 85016915186     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines3030620     Document Type: Review

References (120)

1. + T cells collaborate with macrophages to protect against blood-stage murine malaria. Elife 2015, doi:10.7554/eLife.04232.
2. Barth, H.; Rybczynska, J.; Patient, R.; Choi, Y.; Sapp, R.K.; Baumert, T.F.; Krawczynski, K.; Liang, T.J. Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Hepatology 2011, 54, 1135-1148.
3. Holz, L.; Rehermann, B. T cell responses in hepatitis C virus infection: Historical overview and goals for future research. Antivir. Res. 2015, 114, 96-105.
4. + T-cell targeting of specific epitopes. J. Virol. 2014, 88, 12937-12948.
5. De Souza, J.B. Protective immunity against malaria after vaccination. Parasite Immunol. 2014, 36, 131-139.
6. Chakraborty, S.; Rahman, T.; Chakravorty, R. Characterization of the protective HIV-1 CTL epitopes and the corresponding HLA class I alleles: A step towards designing CTL based HIV-1 vaccine. Adv. Virol. 2014, doi:10.1155/2014/321974.
7. + T cell responses to malaria liver stages by genome-wide epitope profiling. PLoS Pathog. 2013, 9, e1003303.
8. + T cells in human melanoma. Nat. Med. 2015, 21, 81-85.
9. Frosig, T.M.; Lyngaa, R.; Met, O.; Larsen, S.K.; Donia, M.; Svane, I.M.; Thor Straten, P.; Hadrup, S.R. Broadening the repertoire of melanoma-associated T-cell epitopes. Cancer Immunol. Immunother. 2015, 64, 609-620.
10. Riedmann, E.M. Chinese biotech partnership brings first hepatitis E vaccine to the market. Hum. Vaccines Immunother. 2012, 8, 1743-1744.
11. Safety and immunogenicity of norovirus bivalent virus-like particle vaccine in healthy adults. Available online: https://clinicaltrials.gov/ct2/show/NCT02142504 (accessed on 11 July 2015).
12. Trial to evaluate safety and immunogenicity of trivalent seasonal influenza virus-like particle (VLP) vaccine (recombinant). Available online: https://clinicaltrials.gov/ct2/show/NCT00903552 (accessed on 11 July 2015).
13. Immunogenicity, safety and tolerability of a plant-derived seasonal virus-like-particle quadrivalent influenza vaccine in adults. Available online: https://clinicaltrials.gov/ct2/show/NCT02233816 (accessed on 11 July 2015).
14. Sun, S.; Gao, F.; Mao, Q.; Shao, J.; Jiang, L.; Liu, D.; Wang, Y.; Yao, X.; Wu, X.; Sun, B.; et al. Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice. Hum. Vaccines Immunother. 2015, doi:10.1080/21645515.2015.1053675.
15. Kim, M.C.; Song, J.M.; O, E.; Kwon, Y.M.; Lee, Y.J.; Compans, R.W.; Kang, S.M. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol. Ther. 2013, 21, 485-492.
16. Kim, S.H.; Chen, S.; Jiang, X.; Green, K.Y.; Samal, S.K. Immunogenicity of newcastle disease virus vectors expressing norwalk virus capsid protein in the presence or absence of VP2 protein. Virology 2015, 484, 163-169.
17. Batista, F.D.; Harwood, N.E. The who, how and where of antigen presentation to B cells. Nat. Rev. Immunol. 2009, 9, 15-27.
18. Fifis, T.; Gamvrellis, A.; Crimeen-Irwin, B.; Pietersz, G.A.; Li, J.; Mottram, P.L.; McKenzie, I.F.; Plebanski, M. Size-dependent immunogenicity: Therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 2004, 173, 3148-3154.
19. Li, X.; Sloat, B.R.; Yanasarn, N.; Cui, Z. Relationship between the size of nanoparticles and their adjuvant activity: Data from a study with an improved experimental design. Eur. J. Pharm. Biopharm. 2011, 78, 107-116.
20. Li, X.; Aldayel, A.M.; Cui, Z. Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles. J. Control. Release 2014, 173, 148-157.
21. Bershteyn, A.; Hanson, M.C.; Crespo, M.P.; Moon, J.J.; Li, A.V.; Suh, H.; Irvine, D.J. Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. J. Control. Release 2012, 157, 354-365.
22. + T cell response during cross-priming. J. Immunol. 2006, 176, 4682-4689.
23. Kolumam, G.A.; Thomas, S.; Thompson, L.J.; Sprent, J.; Murali-Krishna, K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 2005, 202, 637-650.
24. + T cells stimulated by virus-induced type I interferon. Nat. Immunol. 2003, 4, 1009-1015.
25. Le Bon, A.; Schiavoni, G.; D'Agostino, G.; Gresser, I.; Belardelli, F.; Tough, D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14, 461-470.
26. Cucak, H.; Yrlid, U.; Reizis, B.; Kalinke, U.; Johansson-Lindbom, B. Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. Immunity 2009, 31, 491-501.
27. Kammer, A.R.; Amacker, M.; Rasi, S.; Westerfeld, N.; Gremion, C.; Neuhaus, D.; Zurbriggen, R. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Vaccine 2007, 25, 7065-7074.
28. Cubas, R.; Zhang, S.; Kwon, S.; Sevick-Muraca, E.M.; Li, M.; Chen, C.; Yao, Q. Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J. Immunother. 2009, 32, 118-128.
29. Pinto, L.A.; Viscidi, R.; Harro, C.D.; Kemp, T.J.; Garcia-Pineres, A.J.; Trivett, M.; Demuth, F.; Lowy, D.R.; Schiller, J.T.; Berzofsky, J.A.; et al. Cellular immune responses to HPV-18,-31, and-53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 2006, 353, 451-462.
30. Quan, F.S.; Huang, C.; Compans, R.W.; Kang, S.M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 2007, 81, 3514-3524.
31. Win, S.J.; Ward, V.K.; Dunbar, P.R.; Young, S.L.; Baird, M.A. Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway. Immunol. Cell Biol. 2011, 89, 681-688.
32. − dendritic cells: A dispensable role for tap. Eur. J. Immunol. 2002, 32, 818-825.
33. Leclerc, D.; Beauseigle, D.; Denis, J.; Morin, H.; Pare, C.; Lamarre, A.; Lapointe, R. Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells. J. Virol. 2007, 81, 1319-1326.
34. Peacey, M.; Wilson, S.; Perret, R.; Ronchese, F.; Ward, V.K.; Young, V.; Young, S.L.; Baird, M.A. Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response. Vaccine 2008, 26, 5334-5337.
35. Cubas, R.; Zhang, S.; Li, M.; Chen, C.; Yao, Q. Chimeric trop2 virus-like particles: A potential immunotherapeutic approach against pancreatic cancer. J. Immunother. 2011, 34, 251-263.
36. Speiser, D.E.; Schwarz, K.; Baumgaertner, P.; Manolova, V.; Devevre, E.; Sterry, W.; Walden, P.; Zippelius, A.; Conzett, K.B.; Senti, G.; et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J. Immunother. 2010, 33, 848-858.
37. Ma, Y.; Li, J. Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: A new vaccine candidate against an important noncultivable virus. J. Virol. 2011, 85, 2942-2952.
38. Zaiss, A.K.; Machado, H.B.; Herschman, H.R. The influence of innate and pre-existing immunity on adenovirus therapy. J. Cell. Biochem. 2009, 108, 778-790.
39. Fausther-Bovendo, H.; Kobinger, G.P. Pre-existing immunity against AD vectors: Humoral, cellular, and innate response, what's important? Hum. Vaccines Immunother. 2014, 10, 2875-2884.
40. Kemnade, J.O.; Seethammagari, M.; Collinson-Pautz, M.; Kaur, H.; Spencer, D.M.; McCormick, A.A. Tobacco mosaic virus efficiently targets DC uptake, activation and antigen-specific T cell responses in vivo. Vaccine 2014, 32, 4228-4233.
41. Mallajosyula, J.K.; Hiatt, E.; Hume, S.; Johnson, A.; Jeevan, T.; Chikwamba, R.; Pogue, G.P.; Bratcher, B.; Haydon, H.; Webby, R.J.; et al. Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge. Hum. Vaccines Immunother. 2014, 10, 586-595.
42. Dalsgaard, K.; Uttenthal, A.; Jones, T.D.; Xu, F.; Merryweather, A.; Hamilton, W.D.; Langeveld, J.P.; Boshuizen, R.S.; Kamstrup, S.; Lomonossoff, G.P.; et al. Plant-derived vaccine protects target animals against a viral disease. Nat. Biotechnol. 1997, 15, 248-252.
43. Langeveld, J.P.; Brennan, F.R.; Martinez-Torrecuadrada, J.L.; Jones, T.D.; Boshuizen, R.S.; Vela, C.; Casal, J.I.; Kamstrup, S.; Dalsgaard, K.; Meloen, R.H.; et al. Inactivated recombinant plant virus protects dogs from a lethal challenge with canine parvovirus. Vaccine 2001, 19, 3661-3670.
44. Brennan, F.R.; Bellaby, T.; Helliwell, S.M.; Jones, T.D.; Kamstrup, S.; Dalsgaard, K.; Flock, J.I.; Hamilton, W.D. Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice. J. Virol. 1999, 73, 930-938.
45. Brennan, F.R.; Gilleland, L.B.; Staczek, J.; Bendig, M.M.; Hamilton, W.D.; Gilleland, H.E., Jr. A chimaeric plant virus vaccine protects mice against a bacterial infection. Microbiology 1999, 145, 2061-2067.
46. Brennan, F.R.; Jones, T.D.; Longstaff, M.; Chapman, S.; Bellaby, T.; Smith, H.; Xu, F.; Hamilton, W.D.; Flock, J.I. Immunogenicity of peptides derived from a fibronectin-binding protein of S. Aureus expressed on two different plant viruses. Vaccine 1999, 17, 1846-1857.
47. McInerney, T.L.; Brennan, F.R.; Jones, T.D.; Dimmock, N.J. Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide. Vaccine 1999, 17, 1359-1368.
48. Rennermalm, A.; Li, Y.H.; Bohaufs, L.; Jarstrand, C.; Brauner, A.; Brennan, F.R.; Flock, J.I. Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat. Vaccine 2001, 19, 3376-3383.
49. Miermont, A.; Barnhill, H.; Strable, E.; Lu, X.; Wall, K.A.; Wang, Q.; Finn, M.G.; Huang, X. Cowpea mosaic virus capsid: A promising carrier for the development of carbohydrate based antitumor vaccines. Chemistry 2008, 14, 4939-4947.
50. Nicholas, B.L.; Brennan, F.R.; Hamilton, W.D.; Wakelin, D. Effect of priming/booster immunisation protocols on immune response to canine parvovirus peptide induced by vaccination with a chimaeric plant virus construct. Vaccine 2003, 21, 2441-2447.
51. Nicholas, B.L.; Brennan, F.R.; Martinez-Torrecuadrada, J.L.; Casal, J.I.; Hamilton, W.D.; Wakelin, D. Characterization of the immune response to canine parvovirus induced by vaccination with chimaeric plant viruses. Vaccine 2002, 20, 2727-2734.
52. Kaltgrad, E.; Sen Gupta, S.; Punna, S.; Huang, C.Y.; Chang, A.; Wong, C.H.; Finn, M.G.; Blixt, O. Anti-carbohydrate antibodies elicited by polyvalent display on a viral scaffold. Chembiochem 2007, 8, 1455-1462.
53. Durrani, Z.; McInerney, T.L.; McLain, L.; Jones, T.; Bellaby, T.; Brennan, F.R.; Dimmock, N.J. Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. J. Immunol. Methods 1998, 220, 93-103.
54. Taylor, K.M.; Lin, T.; Porta, C.; Mosser, A.G.; Giesing, H.A.; Lomonossoff, G.P.; Johnson, J.E. Influence of three-dimensional structure on the immunogenicity of a peptide expressed on the surface of a plant virus. J. Mol. Recognit. 2000, 13, 71-82.
55. Gonzalez, M.J.; Plummer, E.M.; Rae, C.S.; Manchester, M. Interaction of cowpea mosaic virus (CPMV) nanoparticles with antigen presenting cells in vitro and in vivo. PLoS ONE 2009, 4, e7981.
56. Marusic, C.; Rizza, P.; Lattanzi, L.; Mancini, C.; Spada, M.; Belardelli, F.; Benvenuto, E.; Capone, I. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J. Virol. 2001, 75, 8434-8439.
57. Lico, C.; Mancini, C.; Italiani, P.; Betti, C.; Boraschi, D.; Benvenuto, E.; Baschieri, S. Plant-produced potato virus X chimeric particles displaying an influenza virus-derived peptide activate specific CD8+ T cells in mice. Vaccine 2009, 27, 5069-5076.
58. Uhde-Holzem, K.; Schlosser, V.; Viazov, S.; Fischer, R.; Commandeur, U. Immunogenic properties of chimeric potato virus X particles displaying the hepatitis C virus hypervariable region I peptide R9. J. Virol. Methods 2010, 166, 12-20.
59. Marconi, G.; Albertini, E.; Barone, P.; de Marchis, F.; Lico, C.; Marusic, C.; Rutili, D.; Veronesi, F.; Porceddu, A. In planta production of two peptides of the classical swine fever virus (CSFV) E2 glycoprotein fused to the coat protein of potato virus X. BMC Biotechnol. 2006, doi:10.1186/1472-6750-6-29.
60. Jobsri, J.; Allen, A.; Rajagopal, D.; Shipton, M.; Kanyuka, K.; Lomonossoff, G.P.; Ottensmeier, C.; Diebold, S.S.; Stevenson, F.K.; Savelyeva, N. Plant virus particles carrying tumour antigen activate TLR7 and induce high levels of protective antibody. PLoS ONE 2015, 10, e0118096.
61. Massa, S.; Simeone, P.; Muller, A.; Benvenuto, E.; Venuti, A.; Franconi, R. Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. Hum. Gene Ther. 2008, 19, 354-364.
62. Smith, M.L.; Lindbo, J.A.; Dillard-Telm, S.; Brosio, P.M.; Lasnik, A.B.; McCormick, A.A.; Nguyen, L.V.; Palmer, K.E. Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology 2006, 348, 475-488.
63. Jiang, L.; Li, Q.; Li, M.; Zhou, Z.; Wu, L.; Fan, J.; Zhang, Q.; Zhu, H.; Xu, Z. A modified tmv-based vector facilitates the expression of longer foreign epitopes in tobacco. Vaccine 2006, 24, 109-115.
64. Palmer, K.E.; Benko, A.; Doucette, S.A.; Cameron, T.I.; Foster, T.; Hanley, K.M.; McCormick, A.A.; McCulloch, M.; Pogue, G.P.; Smith, M.L.; et al. Protection of rabbits against CUTANEOUS papillomavirus infection using recombinant tobacco mosaic virus containing l2 capsid epitopes. Vaccine 2006, 24, 5516-5525.
65. Staczek, J.; Bendahmane, M.; Gilleland, L.B.; Beachy, R.N.; Gilleland, H.E., Jr. Immunization with a chimeric tobacco mosaic virus containing an epitope of outer membrane protein f of Pseudomonas aeruginosa provides protection against challenge with P. aeruginosa. Vaccine 2000, 18, 2266-2274.
66. Koo, M.; Bendahmane, M.; Lettieri, G.A.; Paoletti, A.D.; Lane, T.E.; Fitchen, J.H.; Buchmeier, M.J.; Beachy, R.N. Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc. Natl. Acad. Sci. USA 1999, 96, 7774-7779.
67. McCormick, A.A.; Corbo, T.A.; Wykoff-Clary, S.; Nguyen, L.V.; Smith, M.L.; Palmer, K.E.; Pogue, G.P. Tmv-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models. Vaccine 2006, 24, 6414-6423.
68. McCormick, A.A.; Corbo, T.A.; Wykoff-Clary, S.; Palmer, K.E.; Pogue, G.P. Chemical conjugate tmv-peptide bivalent fusion vaccines improve cellular immunity and tumor protection. Bioconjug. Chem. 2006, 17, 1330-1338.
69. Piazzolla, G.; Nuzzaci, M.; Tortorella, C.; Panella, E.; Natilla, A.; Boscia, D.; de Stradis, A.; Piazzolla, P.; Antonaci, S. Immunogenic properties of a chimeric plant virus expressing A hepatitis C virus (HCV)-derived epitope: New prospects for an HCV vaccine. J. Clin. Immunol. 2005, 25, 142-152.
70. Nuzzaci, M.; Piazzolla, G.; Vitti, A.; Lapelosa, M.; Tortorella, C.; Stella, I.; Natilla, A.; Antonaci, S.; Piazzolla, P. Cucumber mosaic virus as a presentation system for a double hepatitis C virus-derived epitope. Arch. Virol. 2007, 152, 915-928.
71. Jones, R.M.; Chichester, J.A.; Mett, V.; Jaje, J.; Tottey, S.; Manceva, S.; Casta, L.J.; Gibbs, S.K.; Musiychuk, K.; Shamloul, M.; et al. A plant-produced PFS25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice. PLoS ONE 2013, 8, e79538.
72. Yusibov, V.; Mett, V.; Mett, V.; Davidson, C.; Musiychuk, K.; Gilliam, S.; Farese, A.; Macvittie, T.; Mann, D. Peptide-based candidate vaccine against respiratory syncytial virus. Vaccine 2005, 23, 2261-2265.
73. Denis, J.; Acosta-Ramirez, E.; Zhao, Y.; Hamelin, M.E.; Koukavica, I.; Baz, M.; Abed, Y.; Savard, C.; Pare, C.; Lopez Macias, C.; et al. Development of a universal influenza a vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008, 26, 3395-3403.
74. Babin, C.; Majeau, N.; Leclerc, D. Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP. J. Nanobiotechnol. 2013, doi:10.1186/1477-3155-11-10.
75. Denis, J.; Majeau, N.; Acosta-Ramirez, E.; Savard, C.; Bedard, M.C.; Simard, S.; Lecours, K.; Bolduc, M.; Pare, C.; Willems, B.; et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: Evidence for the critical function of multimerization. Virology 2007, 363, 59-68.
76. Hanafi, L.A.; Bolduc, M.; Gagne, M.E.; Dufour, F.; Langelier, Y.; Boulassel, M.R.; Routy, J.P.; Leclerc, D.; Lapointe, R. Two distinct chimeric potexviruses share antigenic cross-presentation properties of mhc class I epitopes. Vaccine 2010, 28, 5617-5626.
77. Lacasse, P.; Denis, J.; Lapointe, R.; Leclerc, D.; Lamarre, A. Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation. J. Virol. 2008, 82, 785-794.
78. Mathieu, C.; Rioux, G.; Dumas, M.C.; Leclerc, D. Induction of innate immunity in lungs with virus-like nanoparticles leads to protection against influenza and Streptococcus pneumoniae challenge. Nanomed. Nanotechnol. Biol. Med. 2013, 9, 839-848.
79. Lebel, M.E.; Daudelin, J.F.; Chartrand, K.; Tarrab, E.; Kalinke, U.; Savard, P.; Labrecque, N.; Leclerc, D.; Lamarre, A. Nanoparticle adjuvant sensing by TLR7 enhances CD8+ T cell-mediated protection from listeria monocytogenes infection. J. Immunol. 2014, 192, 1071-1078.
80. Acosta-Ramirez, E.; Perez-Flores, R.; Majeau, N.; Pastelin-Palacios, R.; Gil-Cruz, C.; Ramirez-Saldana, M.; Manjarrez-Orduno, N.; Cervantes-Barragan, L.; Santos-Argumedo, L.; Flores-Romo, L.; et al. Translating innate response into long-lasting antibody response by the intrinsic antigen-adjuvant properties of papaya mosaic virus. Immunology 2008, 124, 186-197.
81. Savard, C.; Guerin, A.; Drouin, K.; Bolduc, M.; Laliberte-Gagne, M.E.; Dumas, M.C.; Majeau, N.; Leclerc, D. Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. PLoS ONE 2011, 6, e21522.
82. Yang, C.D.; Liao, J.T.; Lai, C.Y.; Jong, M.H.; Liang, C.M.; Lin, Y.L.; Lin, N.S.; Hsu, Y.H.; Liang, S.M. Induction of protective immunity in swine by recombinant bamboo mosaic virus expressing foot-and-mouth disease virus epitopes. BMC Biotechnol. 2007, doi:10.1186/1472-6750-7-62.
83. Chen, T.H.; Chen, T.H.; Hu, C.C.; Liao, J.T.; Lee, C.W.; Liao, J.W.; Lin, M.Y.; Liu, H.J.; Wang, M.Y.; Lin, N.S.; et al. Induction of protective immunity in chickens immunized with plant-made chimeric bamboo mosaic virus particles expressing very virulent infectious bursal disease virus antigen. Virus Res. 2012, 166, 109-115.
84. Joelson, T.; Akerblom, L.; Oxelfelt, P.; Strandberg, B.; Tomenius, K.; Morris, T.J. Presentation of a foreign peptide on the surface of tomato bushy stunt virus. J. Gen. Virol. 1997, 78, 1213-1217.
85. Fernandez-Fernandez, M.R.; Martinez-Torrecuadrada, J.L.; Casal, J.I.; Garcia, J.A. Development of an antigen presentation system based on plum pox potyvirus. FEBS Lett. 1998, 427, 229-235.
86. Fernandez-Fernandez, M.R.; Martinez-Torrecuadrada, J.L.; Roncal, F.; Dominguez, E.; Garcia, J.A. Identification of immunogenic hot spots within plum pox potyvirus capsid protein for efficient antigen presentation. J. Virol. 2002, 76, 12646-12653.
87. Petukhova, N.V.; Gasanova, T.V.; Ivanov, P.A.; Atabekov, J.G. High-level systemic expression of conserved influenza epitope in plants on the surface of rod-shaped chimeric particles. Viruses 2014, 6, 1789-1800.
88. Natilla, A.; Piazzolla, G.; Nuzzaci, M.; Saldarelli, P.; Tortorella, C.; Antonaci, S.; Piazzolla, P. Cucumber mosaic virus as carrier of a hepatitis C virus-derived epitope. Arch. Virol. 2004, 149, 137-154.
89. Thanavala, Y.; Mahoney, M.; Pal, S.; Scott, A.; Richter, L.; Natarajan, N.; Goodwin, P.; Arntzen, C.J.; Mason, H.S. Immunogenicity in humans of an edible vaccine for hepatitis B. Proc. Natl. Acad. Sci. USA 2005, 102, 3378-3382.
90. Arakawa, T.; Chong, D.K.; Langridge, W.H. Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nat. Biotechnol. 1998, 16, 292-297.
91. Muthamilselvan, T.; Lee, C.W.; Cho, Y.H.; Wu, F.C.; Hu, C.C.; Liang, Y.C.; Lin, N.S.; Hsu, Y.H. A transgenic plant cell-suspension system for expression of epitopes on chimeric bamboo mosaic virus particles. Plant Biotechnol. J. 2015, doi:10.1111/pbi.12377.
92. Plchova, H.; Moravec, T.; Hoffmeisterova, H.; Folwarczna, J.; Cerovska, N. Expression of human papillomavirus 16 E7ggg oncoprotein on N-and C-terminus of potato virus X coat protein in bacterial and plant cells. Protein Expr. Purif. 2011, 77, 146-152.
93. Kadri, A.; Wege, C.; Jeske, H. In vivo self-assembly of TMV-like particles in yeast and bacteria for nanotechnological applications. J. Virol. Methods 2013, 189, 328-340.
94. Brumfield, S.; Willits, D.; Tang, L.; Johnson, J.E.; Douglas, T.; Young, M. Heterologous expression of the modified coat protein of cowpea chlorotic mottle bromovirus results in the assembly of protein cages with altered architectures and function. J. Gen. Virol. 2004, 85, 1049-1053.
95. Saunders, K.; Sainsbury, F.; Lomonossoff, G.P. Efficient generation of cowpea mosaic virus empty virus-like particles by the proteolytic processing of precursors in insect cells and plants. Virology 2009, 393, 329-337.
96. Kumar, S.; Ochoa, W.; Singh, P.; Hsu, C.; Schneemann, A.; Manchester, M.; Olson, M.; Reddy, V. Tomato bushy stunt virus (TBSV), a versatile platform for polyvalent display of antigenic epitopes and vaccine design. Virology 2009, 388, 185-190.
97. Mueller, A.; Kadri, A.; Jeske, H.; Wege, C. In vitro assembly of tobacco mosaic virus coat protein variants derived from fission yeast expression clones or plants. J. Virol. Methods 2010, 166, 77-85.
98. Arkhipenko, M.V.; Petrova, E.K.; Nikitin, N.A.; Protopopova, A.D.; Dubrovin, E.V.; Yaminskii, I.V.; Rodionova, N.P.; Karpova, O.V.; Atabekov, J.G. Characteristics of artificial virus-like particles assembled in vitro from potato virus X coat protein and foreign viral RNAs. Acta Nat. 2011, 3, 40-46.
99. Tyulkina, L.G.; Skurat, E.V.; Frolova, O.Y.; Komarova, T.V.; Karger, E.M.; Atabekov, I.G. New viral vector for superproduction of epitopes of vaccine proteins in plants. Acta Nat. 2011, 3, 73-82.
100. Smith, M.L.; Corbo, T.; Bernales, J.; Lindbo, J.A.; Pogue, G.P.; Palmer, K.E.; McCormick, A.A. Assembly of trans-encapsidated recombinant viral vectors engineered from tobacco mosaic virus and semliki forest virus and their evaluation as immunogens. Virology 2007, 358, 321-333.
101. Atabekov, J.; Nikitin, N.; Arkhipenko, M.; Chirkov, S.; Karpova, O. Thermal transition of native tobacco mosaic virus and rna-free viral proteins into spherical nanoparticles. J. Gen. Virol. 2011, 92, 453-456.
102. Karpova, O.; Nikitin, N.; Chirkov, S.; Trifonova, E.; Sheveleva, A.; Lazareva, E.; Atabekov, J. Immunogenic compositions assembled from tobacco mosaic virus-generated spherical particle platforms and foreign antigens. J. Gen. Virol.2012, 93, 400-407.
103. Phelps, J.P.; Dang, N.; Rasochova, L. Inactivation and purification of cowpea mosaic virus-like particles displaying peptide antigens from Bacillus anthracis. J. Virol. Methods 2007, 141, 146-153.
104. Rae, C.S.; Khor, I.W.; Wang, Q.; Destito, G.; Gonzalez, M.J.; Singh, P.; Thomas, D.M.; Estrada, M.N.; Powell, E.; Finn, M.G.; et al. Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology 2005, 343, 224-235.
105. Vitti, A.; Piazzolla, G.; Condelli, V.; Nuzzaci, M.; Lanorte, M.T.; Boscia, D.; de Stradis, A.; Antonaci, S.; Piazzolla, P.; Tortorella, C. Cucumber mosaic virus as the expression system for a potential vaccine against Alzheimer's disease. J. Virol. Methods 2010, 169, 332-340.
106. Rioux, G.; Majeau, N.; Leclerc, D. Mapping the surface-exposed regions of papaya mosaic virus nanoparticles. FEBS J. 2012, 279, 2004-2011.
107. Wu, L.; Jiang, L.; Zhou, Z.; Fan, J.; Zhang, Q.; Zhu, H.; Han, Q.; Xu, Z. Expression of foot-and-mouth disease virus epitopes in tobacco by a tobacco mosaic virus-based vector. Vaccine 2003, 21, 4390-4398.
108. Petukhova, N.V.; Gasanova, T.V.; Stepanova, L.A.; Rusova, O.A.; Potapchuk, M.V.; Korotkov, A.V.; Skurat, E.V.; Tsybalova, L.M.; Kiselev, O.I.; Ivanov, P.A.; et al. Immunogenicity and protective efficacy of candidate universal influenza a nanovaccines produced in plants by tobacco mosaic virus-based vectors. Curr. Pharm. Des. 2013, 19, 5587-5600.
109. Bendahmane, M.; Koo, M.; Karrer, E.; Beachy, R.N. Display of epitopes on the surface of tobacco mosaic virus: Impact of charge and isoelectric point of the epitope on virus-host interactions. J. Mol. Biol. 1999, 290, 9-20.
110. Yin, Z.; Nguyen, H.G.; Chowdhury, S.; Bentley, P.; Bruckman, M.A.; Miermont, A.; Gildersleeve, J.C.; Wang, Q.; Huang, X. Tobacco mosaic virus as a new carrier for tumor associated carbohydrate antigens. Bioconjug. Chem. 2012, 23, 1694-1703.
111. Rioux, G.; Babin, C.; Majeau, N.; Leclerc, D. Engineering of papaya mosaic virus (PapMV) nanoparticles through fusion of the HA11 peptide to several putative surface-exposed sites. PLoS ONE 2012, 7, e31925.
112. Porta, C.; Spall, V.E.; Findlay, K.C.; Gergerich, R.C.; Farrance, C.E.; Lomonossoff, G.P. Cowpea mosaic virus-based chimaeras. Effects of inserted peptides on the phenotype, host range, and transmissibility of the modified viruses. Virology 2003, 310, 50-63.
113. Uhde-Holzem, K.; Fischer, R.; Commandeur, U. Genetic stability of recombinant potato virus X virus vectors presenting foreign epitopes. Arch. Virol. 2007, 152, 805-811.
114. Werner, S.; Marillonnet, S.; Hause, G.; Klimyuk, V.; Gleba, Y. Immunoabsorbent nanoparticles based on a tobamovirus displaying protein a. Proc. Natl. Acad. Sci. USA 2006, 103, 17678-17683.
115. Plotkin, S.A. Vaccines: Correlates of vaccine-induced immunity. Clin. Infect. Dis. 2008, 47, 401-409.
116. Khor, I.W.; Lin, T.; Langedijk, J.P.; Johnson, J.E.; Manchester, M. Novel strategy for inhibiting viral entry by use of a cellular receptor-plant virus chimera. J. Virol. 2002, 76, 4412-4419.
117. Brennan, F.R.; Jones, T.D.; Gilleland, L.B.; Bellaby, T.; Xu, F.; North, P.C.; Thompson, A.; Staczek, J.; Lin, T.; Johnson, J.E.; et al. Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus. Microbiology 1999, 145, 211-220.
118. Storni, T.; Lechner, F.; Erdmann, I.; Bachi, T.; Jegerlehner, A.; Dumrese, T.; Kundig, T.M.; Ruedl, C.; Bachmann, M.F. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J. Immunol. 2002, 168, 2880-2886.
119. Safety and Reactogenicity of a PAL Combined with Seasonal Flu Vaccine in Healthy Adults. Available online: https://clinicaltrials.gov/ct2/show/NCT02188810 (accessed on 11 July 2015).
120. Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults. Available online: https://clinicaltrials.gov/ct2/show/NCT02013687? term=Pfs25&rank=4 (accessed on 11 July 2015).